智通财经APP讯，药明康德(02359)公布，2025年8月11日耗资约2799.56万元回购30.7万股A股股份。 ...

格隆汇8月11日丨药明康德(02359.HK)发布公告，2025年8月11日耗资2799.56万元人民币回购30.7万股A 股，回购价格每股90.61-92.33元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年8月8日 | 2,485,141,055 | | 0 | | 2,485,141,055 | | 1). 其他 (請註明) | | | % | | | | | 參見B部 | | | ...

Summary of WuXi XDC Cayman Inc. Conference Call Company and Industry Overview - **Company**: WuXi XDC Cayman Inc. - **Industry**: China Healthcare Key Points and Arguments 1. **MSCI Inclusion Impact**: Inclusion in the MSCI China All Share Index is expected to broaden the investor base, providing comfort to portfolio managers regarding stock tradeability and interest from generalist investors [5][1] 2. **Growth and Earnings Visibility**: WuXi XDC is noted for having the highest growth and earnings visibility within the WuXi family, with an expected earnings CAGR of over 30% from 2024 to 2028 [2][1] 3. **Competitive Position**: The company has a strong competitive moat and leading indicators, making it a top pick compared to its peers, WuXi Biologics and WuXi AppTec [2][1] 4. **Market Capitalization Growth**: From the beginning of 2025 to the end of July, WuXi XDC's market cap increased from US$4.7 billion to US$8.8 billion, representing an 87% growth, significantly outperforming the 35% growth of the healthcare sector [5][1] 5. **Financial Performance**: Preliminary results for the first half of 2025 exceeded expectations, and a doubling of formulation capacity is anticipated, indicating conservative guidance and a significant backlog addition [2][1] 6. **Valuation Metrics**: The company’s price target is set at HK$60.00, with a current price of HK$56.05, indicating a 7% upside potential. The market cap is approximately RMB 61.45 billion [3][1] 7. **Earnings Projections**: Projected EPS for the fiscal years ending in 2025, 2026, and 2027 are RMB 1.24, RMB 1.66, and RMB 2.17 respectively, with revenues expected to grow from RMB 4.05 billion in 2024 to RMB 9.66 billion in 2027 [3][1] 8. **Risks Identified**: Potential risks include a deceleration in biotech funding, missed sales expectations for late-stage projects, and lower-than-expected gross margin improvements from new facilities [8][1] Additional Important Information - **Analyst Ratings**: The stock is rated as "Overweight" with an attractive industry view, indicating a positive outlook for the company compared to its peers [3][1] - **Market Dynamics**: The inclusion in the MSCI index is expected to enhance liquidity, potentially shifting investment preferences towards WuXi XDC over its parent company [2][1] - **Long-term Growth Strategy**: The company is positioned for significant growth, supported by its development stage and market conditions, with a focus on expanding its capabilities and market presence [6][1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年8月8日 | 7). | 購回股份(或其他證券)但沒有註銷 | 282,748 | 0.01 % | RMB | 70.77 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 | | | | | | | 通函，及於2025年4月29日刊發的投票結果公告。 | | | | | | | 於2025年7月4日，本公司實施2025年第一次回購，并回購282,748股A | | | | | | | 股股份。 | | | | | | | 變動日期 2025年7月4日 | | | | | | 8). | 購回股份(或其他證券)但沒有註銷 | 287,026 | | | | | | | | 0.01 % | RMB | 69.71 | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月2 ...

药明康德（603259）(02359)发布公告，于2025年8月8日斥资2799.74万元回购A股股份30.83万股，每股 回购价格为89.58-91.5元。 ...

智通财经APP讯，药明康德(02359)发布公告，于2025年8月8日斥资2799.74万元回购A股股份30.83万 股，每股回购价格为89.58-91.5元。 该信息由智通财经网提供 ...

Group 1 - Company WuXi AppTec (02359.HK) announced a share buyback plan on August 8, 2025, involving an expenditure of 27.9974 million RMB to repurchase 308,300 A-shares [1] - The buyback price per share is set between 89.58 and 91.5 RMB [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年8月8日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行 ...

Core Viewpoint - WuXi AppTec's stock price on August 7 was reported at 91.21 CNY, reflecting a decrease of 2.37 CNY from the previous trading day, indicating market volatility and investor sentiment [1] Company Summary - WuXi AppTec is a leading global pharmaceutical research and development service provider, offering new drug development and production services to pharmaceutical, biotechnology, and medical device companies [1] - For the first half of 2025, the company reported revenue of 20.799 billion CNY and a net profit attributable to shareholders of 8.561 billion CNY [1] Financial Activities - On August 7, the company completed the issuance of 73.8 million H-shares at a price of 104.27 HKD per share, raising a net amount of 7.647 billion HKD [1] - Of the raised funds, 90% will be allocated for global expansion and capacity building, while 10% will be used to supplement operational funds [1] - On the same day, the company repurchased 310,000 A-shares at a cost of 28 million CNY [1] Market Activity - On August 7, WuXi AppTec experienced a net outflow of 663 million CNY in principal funds, accounting for 0.29% of its circulating market value [1] - Over the past five trading days, the cumulative net outflow reached 1.525 billion CNY, representing 0.67% of the circulating market value [1]